Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells

Clinical Immunology

Volumn 140, Issue 1, 2011, Pages 92-101

  Lv, Kun ^a   Xu, Wei ^a   Wang, Cuini ^a   Niki, Toshiro ^c   Hirashima, Mitsuomi ^d   Xiong, Sidong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c GalPharma Co Ltd   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

Author keywords

Coxsackievirus; Galectin 9; Myocarditis; Regulatory T cells; Th2

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CREATINE KINASE MB; ECALECTIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; HEART MUSCLE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH2 CELL; UPREGULATION; VIRUS MYOCARDITIS;

ANIMALS; CELL PROLIFERATION; CELL SEPARATION; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GALECTINS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TH2 CELLS;

EID: 79958710291     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.03.017     Document Type: Article

References (38)

1. McManus B.M., Yanagawa B., Rezai N., Luo H., Taylor L., Zhang M., Yuan J., Buckley J., Triche T., Schreiner G., Yang D. Genetic determinants of coxsackievirus B3 pathogenesis. Ann. NY Acad. Sci. 2002, 975:169-179.
2. Tam P.E. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 2006, 19:133-146.
3. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 1994, 68:5126-5132.
4. Huber S.A., Sartini D., Exley M. Vgamma4+ T cells promote autoimmune CD8+ cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4+ Th1 cells. J. Virol. 2002, 76:10785-10790.
5. Opavsky M.A., Penninger J., Aitken K., Wen W.H., Dawood F., Mak T. Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ. Res. 1999, 85:551-558.
6. Huber S.A., Shi C., Budd R.C. Gammadelta T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand. J. Virol. 2002, 76:6487-6494.
7. Jiang Z., Xu W., Li K., Yue Y., Xu L., Ye F., Xiong S. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer. J. Gene Med. 2008, 10:918-929.
8. Shen Y., Xu W., Chu Y.W., Wang Y., Xiong S. CVB3 infection up-regulates the expression of MCP-1 in cardiac myocytes which leads to enhanced migration of mononuclear cells in viral myocarditis. J. Virol. 2004, 78:12548-12556.
9. -regulatory T cells. J. Immunol. 2006, 176:4748-4756.
10. Shevach E.M., Stephens G.L. The GITR-GITRL interaction: co-stimulation or contra-suppression of regulatory activity?. Nat. Rev. Immunol. 2006, 6:613-618.
11. Huber S.A., Feldman A.M., Sartini D. Coxsackievirus B3 induces T regulatory cells which inhibit cardiomyopathy in TNF-transgenic mice. Circ. Res. 2006, 99:1109-1116.
12. Fairweather D., Yusung S., Frisancho S., Barrett M., Gatewood S., Steele R., Rose N.R. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta and IL-18 associated myocarditis and coxsackievirus replication. J. Immunol. 2003, 170:4731-4737.
13. Lane J.R., Neumann D.A., Lafond-Walker A., Herskowitz A., Rose N.R. Interleukin 1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B1 mice. J. Exp. Med. 1992, 175:1123-1129.
14. Sylvia F.K., Jennifer F.N., Davis S.E., Barrett M.A., Gatewood J.L., Njoku D.B., Cihakova D., Silbergeld E.K., Rose N.R., Fairweather D. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J. Immunol. 2006, 176:6411-6415.
15. Saita N., Goto E., Yamamoto T., Cho I., Tsumori K., Kohrogi H., Maruo K., Ono T., Takeya M., Kashio Y., Nakamura K., Hirashima M. Association of galectin-9 with eosinophil apoptosis. Int. Arch. Allergy Immunol. 2002, 128:42-50.
16. Kageshita T., Kashio Y., Yamauchi A., Seki M., AbedinM J., Nishi N., Shoji H., Nakamura T., Ono T., Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 2002, 99:809-816.
17. Wada J., Ota K., Kumar A., Wallner E.I., Kanwar Y.S. Developmental regulation, expression, and apoptotic potential of galectin-9, a b-galactoside binding lectin. J. Clin. Invest. 1997, 99:2452-2461.
18. Matsumoto R., Matsumoto H., Seki M., Hata M., Asano Y., Kanegasaki S., Stevens R.L., Hirashima M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 1998, 273:16976-16984.
19. Kashio Y., Nakamura K., Abedin M.J., Seki M., Nishi N., Yoshida N., Nakamura T., Hirashima M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 2003, 170:3631-3636.
20. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
21. Tsuboi Y., Abe H., Nakagawa R., Oomizu S., Watanabe K., Nishi N., Nakamura T., Yamauchi A., Hirashima M. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin. Immunol. 2007, 124:221-233.
22. Fukushima A., Tamaki S., Ken F. Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. Int. Arch. Allergy Immunol. 2008, 146:36-43.
23. Seki M., Oomizu S., Sakata K., Sakata A., Arikawa T., Watanabe K., Ito K., Takeshita K., Niki T., Saita N., Nishi N., Yamauchi A., Katoh S., Matsukawa A., Kuchroo V., Hirashima M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127:78-88.
24. Sharvan S., Amol S., Hirashima M., Rouse B.T. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J. Immunol. 2009, 182:3191-3201.
25. Henke A., Huber S., Stelzner A., Whitton J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 1995, 69:6720-6728.
26. Nishi N., Itoh A., Fujiyama A., Yoshida N., Araya S., Hirashima M., Shoji H., Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 2005, 579:2058-2064.
27. Mouzaki A., Deraos S., Chatzantoni K. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides. Curr. Med. Chem. 2005, 12:1537-1550.
28. Rook G.A. Th2 cytokines in susceptibility to tuberculosis. Curr. Mol. Med. 2007, 7:327-337.
29. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 2007, 117:1119-1127.
30. Peluso I., Pallone F., Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J. Gastroenterol. 2006, 12:5606-5610.
31. Li K., Xu W., Guo Q., Jiang Z., Wang P., Yue Y., Xiong S. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ. Res. 2009, 105:353-364.
32. Yue Y., Gui J., Xu W., Xiong S. Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization. Mol. Immunol. 2011, 48:706-713.
33. Di Giovine F.S., Nuki G., Duff G.W. Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 1988, 47:768-772.
34. Yokota K., Miyazaki T., Hirano M., Akiyama Y., Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 2006, 33:463-471.
35. Rathanaswami P., Hachicha M., Wong W.L., Schall T.J., McColl S.R. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. Arthritis Rheum. 1993, 36:1295-1304.
36. Katrib P.P., Tak J.V., Bertouch C., Cuello H.P., McNeil T.J., Smeets Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatol. Oxf. 2001, 40:988-994.
37. Henke A., Zell R., Ehrlich G., Stelzner A. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J. Virol. 2001, 75:8187-8194.
38. Nishio R., Matsumori A., Shioi T., Ishida H., Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 1999, 100:1102-1108.